SEC Form 4 · accession 0000899243-18-028484
Eidos Therapeutics, Inc. · EIDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan C Fox
Officer — See Remarks
Period of report
Nov 5, 2018
Accepted (ET)
Nov 7, 2018 · 7:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001731831
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.20 | Nov 5, 2018 | A | 70,000 | A | — | Nov 5, 2028 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F1The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 70,000 stock options (the "Grant") on November 5, 2018. The shares subject to the Grant shall vest as follows: one quarter of the shares shall vest on November 5, 2019 and the remaining unvested shares shall vest ratably over the following 36 months, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Remarks
President and Chief Medical Officer